Eosinophilic Asthma Clinical Trial
Official title:
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients with eosinophilic asthma.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05398133 -
Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and Asthma
|
||
Recruiting |
NCT04585997 -
Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab".
|
Phase 4 | |
Recruiting |
NCT05985694 -
AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma
|
Phase 2 | |
Completed |
NCT03563521 -
Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma
|
||
Completed |
NCT03469934 -
Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma
|
Phase 2 | |
Enrolling by invitation |
NCT06388889 -
Phase III Long-Term Extension Study With Dexpramipexole
|
Phase 3 | |
Recruiting |
NCT04187976 -
Eosinophils Endotypes in Chronic Airway Inflammatory Diseases
|
||
Recruiting |
NCT05813288 -
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
|
Phase 3 | |
Completed |
NCT01285323 -
A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
|
Phase 3 | |
Completed |
NCT03696914 -
Intense Airway Eosinophilia in Asthma
|
||
Terminated |
NCT01290887 -
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
|
Phase 3 | |
Recruiting |
NCT04228588 -
A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil
|
Phase 4 | |
Recruiting |
NCT05763121 -
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
|
Phase 3 | |
Recruiting |
NCT05748600 -
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
|
Phase 3 | |
Completed |
NCT01508936 -
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
|
Phase 3 | |
Recruiting |
NCT04538937 -
Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils
|
||
Completed |
NCT05002621 -
Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma
|
||
Completed |
NCT04674137 -
XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma
|
Phase 2 | |
Recruiting |
NCT04671446 -
Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma
|
||
Completed |
NCT04046939 -
Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma
|
Phase 2 |